Armando Anido, Chief Executive Officer at Zynerba Pharmaceuticals discusses his company’s lead product candidate ZYN002, a CBD gel currently being evaluated for Fragile X syndrome.

ZTN002 is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is being developed for patients suffering from Fragile X syndrome, ASD in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.